Daniel Mutnick

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

David C. Tully, Paul V. Rucker, D. CHIANELLI et al. · Journal of Medicinal Chemistry · 2017 · 224 citations · Full text

Pathology, Farnesoid X Receptor, Pharmacotherapy +20

Total Synthesis of the <i>Lycopodium</i> Alkaloid (+)-Serratezomine A

Aroop Chandra, Julie A. Pigza, Jeong‐Seok Han et al. · Journal of the American Chemical Society · 2009 · 56 citations · Full text

Bioorganic Chemistry, Engineering, Sensitive Bridging Lactone +12

Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria

Colin K. Skepper, Duncan Armstrong, Carl J. Balibar et al. · Journal of Medicinal Chemistry · 2020 · 36 citations · Full text

The First Azacyclopentenyl Carbinyl Radical Isomerizations (ACCRI):  Independent Use of Steric and Electronic (Polarization) Effects as Gating Elements

Rajesh Viswanathan, Daniel Mutnick, Jeffrey N. Johnston · Journal of the American Chemical Society · 2003 · 35 citations

Combinatorial Chemistry, Gating Elements, Heterocyclic +13

Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor

Phil B. Alper, Thomas H. Marsilje, Daniel Mutnick et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 28 citations · Full text

Drug Target, Biochemistry, Functional Selectivity +9